TrialSignal
Clinical trial intelligence report
A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as an Adjuvant to Chemotherapy in Subjects With Breast Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02527746
Status
COMPLETED
Phase
Phase I
Sponsor
EVIVE Biotechnology
Executive brief
Investment-Ready Snapshot
This clinical trial evaluated the safety and pharmacokinetics of F-627 as an adjuvant to chemotherapy in female breast cancer patients undergoing myelotoxic chemotherapy. The study was conducted by EVIVE Biotechnology in collaboration with Fudan University, involving 18 patients across three dose cohorts.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02527746
Indication
Neutropenia
Modality
small molecule
Target
F-627 (Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein)
Intervention
F-627, EC regimen
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.